UCB’s Bets on Complement Diseases with US$2.1 B Ra Pharma Acquisition

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)

Published: 15 Oct-2019

DOI: 10.3833/pdr.v2019.i10.2461     ISSN: 1756-7874

Section: Mergers & Acquisitions



UCB has agreed to acquire Ra Pharmaceuticals (Ra Pharma), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases of the complement system...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details